Identification

Name
Isoniazid
Accession Number
DB00951  (APRD01055, EXPT01940)
Type
Small Molecule
Groups
Approved
Description

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. [PubChem]

Structure
Thumb
Synonyms
  • 4-pyridinecarbohydrazide
  • INH
  • Isoniazid
  • Isonicotinic acid hydrazide
  • Isonicotinic hydrazide
  • Isonicotinohydrazide
  • Isonicotinoylhydrazide
  • Isonicotinsaeurehydrazid
  • Isonicotinylhydrazine
  • Pyridine-4-carboxylic acid hydrazide
External IDs
NSC-9659
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-isoniazid 300mg TabletsTablet300 mgOralDominion Pharmacal1995-12-31Not applicableCanada
IsoniazidTablet100 mg/1OralRemedy Repack2011-06-212016-10-13Us
IsoniazidTablet300 mg/1OralPd Rx Pharmaceuticals, Inc.1978-12-11Not applicableUs
IsoniazidTablet300 mg/1OralRemedy Repack2011-12-072016-12-13Us
IsoniazidTablet100 mg/1OralEon Labs, Inc.1978-12-11Not applicableUs
IsoniazidTablet100 mg/1OralPd Rx Pharmaceuticals, Inc.1978-12-11Not applicableUs
IsoniazidTablet100 mg/1OralRemedy Repack2016-05-04Not applicableUs
IsoniazidTablet100 mg/1OralRemedy Repack2011-07-192016-10-28Us
IsoniazidTablet300 mg/1OralEon Labs, Inc.1978-12-11Not applicableUs
IsoniazidTablet300 mg/1OralPreferreed Pharmaceuticals Inc.2015-10-07Not applicableUs00185 4350 01 nlmimage10 6b083581
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IsoniazidTablet300 mg/1OralBlenheim Pharmacal, Inc.2013-06-28Not applicableUs
IsoniazidTablet300 mg/1OralPd Rx Pharmaceuticals, Inc.1972-09-01Not applicableUs
IsoniazidTablet300 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
IsoniazidTablet100 mg/1OralTeva1972-09-01Not applicableUs00555 0066 02 nlmimage10 c82b642b
IsoniazidTablet300 mg/1OralVersa Pharm Incorporated1997-09-01Not applicableUs
IsoniazidTablet100 mg/1OralRemedy Repack2014-06-182017-06-20Us
IsoniazidSyrup50 mg/5mLOralMikart, Inc.1997-07-21Not applicableUs
IsoniazidSolution50 mg/5mLOralCmp Pharma, Inc.1983-11-11Not applicableUs
IsoniazidTablet300 mg/1OralDepartment Of State Health Services, Pharmacy Branch1972-09-01Not applicableUs
IsoniazidTablet300 mg/1OralContract Pharmacy Services Pa2010-08-02Not applicableUs
International/Other Brands
Nicozid (Piam) / Nidrazid (Zentiva) / Nydrazid (Sandoz) / Rimicid (Sopharma) / Rimifon (Roche) / Servizid (Novartis) / Tibinide (Meda)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
IsonaRifIsoniazid (150 mg/1) + Rifampicin (300 mg/1)CapsuleOralVersa Pharm Incorporated2005-09-01Not applicableUs
Isotamine B 300Isoniazid (300 mg) + Pyridoxine hydrochloride (15 mg)TabletOralValeant Canada Lp Valeant Canada S.E.C.1967-12-31Not applicableCanada
RifamateIsoniazid (150 mg/1) + Rifampicin (300 mg/1)CapsuleOralSanofi Aventis1975-07-11Not applicableUs
RifaterIsoniazid (50 mg/1) + Pyrazinamide (300 mg/1) + Rifampicin (120 mg/1)Tablet, sugar coatedOralRemedy Repack2010-09-152016-10-13Us
RifaterIsoniazid (50 mg/1) + Pyrazinamide (300 mg/1) + Rifampicin (120 mg/1)Tablet, sugar coatedOralSanofi Aventis1994-05-31Not applicableUs
RifaterIsoniazid (50 mg) + Pyrazinamide (300 mg) + Rifampicin (120 mg)TabletOralSanofi Aventis1995-12-312017-03-29Canada
Categories
UNII
V83O1VOZ8L
CAS number
54-85-3
Weight
Average: 137.1393
Monoisotopic: 137.058911861
Chemical Formula
C6H7N3O
InChI Key
QRXWMOHMRWLFEY-UHFFFAOYSA-N
InChI
InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
IUPAC Name
pyridine-4-carbohydrazide
SMILES
NNC(=O)C1=CC=NC=C1

Pharmacology

Indication

For the treatment of all forms of tuberculosis in which organisms are susceptible.

Structured Indications
Pharmacodynamics

Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. It is a highly specific agent, ineffective against other microorganisms. Isoniazid is bactericidal to rapidly-dividing mycobacteria, but is bacteriostatic if the mycobacterium is slow-growing.

Mechanism of action

Isoniazid is a prodrug and must be activated by bacterial catalase. Specficially, activation is associated with reduction of the mycobacterial ferric KatG catalase-peroxidase by hydrazine and reaction with oxygen to form an oxyferrous enzyme complex. Once activated, isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms. Specifically isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. It is the INH-NAD adduct that acts as a slow, tight-binding competitive inhibitor of InhA.

TargetActionsOrganism
ACatalase-peroxidase
other/unknown
Mycobacterium tuberculosis
AEnoyl-[acyl-carrier-protein] reductase [NADH]
adduct
Mycobacterium tuberculosis
UCytochrome P450 2C8Not AvailableHuman
UCytochrome P450 1A2Not AvailableHuman
UCytochrome P450 3A4Not AvailableHuman
UCytochrome P450 2C19Not AvailableHuman
UDihydrofolate reductaseNot AvailableMycobacterium tuberculosis
Absorption

Readily absorbed following oral administration; however, may undergo significant first pass metabolism. Absorption and bioavailability are reduced when isoniazid is administered with food.

Volume of distribution
Not Available
Protein binding

Very low (0-10%)

Metabolism

Primarily hepatic. Isoniazid is acetylated by N -acetyl transferase to N -acetylisoniazid; it is then biotransformed to isonicotinic acid and monoacetylhydrazine. Monoacetylhydrazine is associated with hepatotoxicity via formation of a reactive intermediate metabolite when N-hydroxylated by the cytochrome P450 mixed oxidase system. The rate of acetylation is genetically determined. Slow acetylators are characterized by a relative lack of hepatic N -acetyltransferase.

Route of elimination

From 50 to 70 percent of a dose of isoniazid is excreted in the urine within 24 hours.

Half life

Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.

Clearance
Not Available
Toxicity

LD50 100 mg/kg (Human, oral). Adverse reactions include rash, abnormal liver function tests, hepatitis, peripheral neuropathy, mild central nervous system (CNS) effects. In vivo, Isoniazid reacts with pyridoxal to form a hydrazone, and thus inhibits generation of pyridoxal phosphate. Isoniazid also combines with pyridoxal phosphate; high doses interfere with the coenzyme function of the latter.

Affected organisms
  • Mycobacteria
  • Mycobacterium tuberculosis
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2E1CYP2E1*4(A;A)---ADR Directly StudiedThe presence of this genotype in CYP2E1 may be associated with an increased risk of drug-induced hepatotoxicity from isoniazid treatment.Details
Arylamine N-acetyltransferase 1NAT1*14ANot AvailableG > A | T > A | C > AADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 1NAT1*14BNot AvailableG > AADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 1NAT1*15Not AvailableC > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 1NAT1*17Not AvailableC > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 1NAT1*19ANot AvailableC > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 1NAT1*19BNot AvailableC > T | C > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 1NAT1*22Not AvailableA > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5ANot AvailableT > C | C > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5BNot AvailableT > C | C > T | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5CNot AvailableT > C | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5DNot AvailableT > CADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5ENot AvailableT > C | G > AADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5FNot AvailableT > C | C > T | C > T | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5GNot AvailableT > C | C > T | C > T | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5HNot AvailableT > C | C > T | A > G | S287 FrameshiftADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5INot AvailableT > C | C > T | A > T | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*5JNot AvailableT > C | C > T | G > AADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*6ANot AvailableG > A | C > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*6BNot AvailableG > AADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*6CNot AvailableG > A | C > T | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*6DNot AvailableG > A | C > T | T > CADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*6ENot AvailableG > A | C > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*7ANot AvailableG > AADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*7BNot AvailableG > A | C > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*10Not AvailableG > AADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*12DNot AvailableG > A | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*14ANot AvailableG > AADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*14BNot AvailableG > A | C > TADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*14CNot AvailableG > A | T > C | C > T | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*14DNot AvailableG > A | C > T | G > AADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*14ENot AvailableG > A | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*14FNot AvailableG > A | T > C | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*14GNot AvailableG > A | C > T | A > GADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*17Not AvailableA > CADR InferredIncreased risk of toxic reactions.Details
Arylamine N-acetyltransferase 2NAT2*19Not AvailableC > TADR InferredIncreased risk of toxic reactions.Details

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of Isoniazid can be decreased when it is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe serum concentration of Isoniazid can be decreased when it is combined with 19-norandrostenedione.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Isoniazid.Experimental, Illicit
5-androstenedioneThe serum concentration of Isoniazid can be decreased when it is combined with 5-androstenedione.Experimental, Illicit
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Isoniazid.Approved
AcetaminophenThe risk or severity of adverse effects can be increased when Isoniazid is combined with Acetaminophen.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Isoniazid.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Isoniazid.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Isoniazid.Approved, Investigational
AlclometasoneThe serum concentration of Isoniazid can be decreased when it is combined with Alclometasone.Approved
AldosteroneThe serum concentration of Isoniazid can be decreased when it is combined with Aldosterone.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Isoniazid.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Isoniazid.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlprenololThe metabolism of Alprenolol can be decreased when combined with Isoniazid.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Isoniazid.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Isoniazid.Experimental, Investigational
AmcinonideThe serum concentration of Isoniazid can be decreased when it is combined with Amcinonide.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Isoniazid.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Isoniazid.Approved
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Isoniazid.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Isoniazid.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Isoniazid.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Isoniazid.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Isoniazid.Approved, Vet Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Isoniazid.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Isoniazid.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Isoniazid.Approved
AndrostenedioneThe serum concentration of Isoniazid can be decreased when it is combined with Androstenedione.Experimental, Illicit
AnecortaveThe serum concentration of Isoniazid can be decreased when it is combined with Anecortave.Investigational
anecortave acetateThe serum concentration of Isoniazid can be decreased when it is combined with anecortave acetate.Investigational
AnilineThe metabolism of Aniline can be decreased when combined with Isoniazid.Experimental
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Isoniazid.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Isoniazid.Approved
AprepitantThe metabolism of Aprepitant can be decreased when combined with Isoniazid.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Isoniazid.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Isoniazid.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Isoniazid.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Isoniazid.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Isoniazid resulting in a loss in efficacy.Approved, Investigational
AstemizoleThe metabolism of Astemizole can be decreased when combined with Isoniazid.Approved, Withdrawn
AtamestaneThe serum concentration of Isoniazid can be decreased when it is combined with Atamestane.Investigational
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Isoniazid.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Isoniazid is combined with Atorvastatin.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Isoniazid.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Isoniazid.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Isoniazid.Investigational
Beclomethasone dipropionateThe serum concentration of Isoniazid can be decreased when it is combined with Beclomethasone dipropionate.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Isoniazid.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Isoniazid.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Isoniazid.Approved, Withdrawn
BetamethasoneThe serum concentration of Isoniazid can be decreased when it is combined with Betamethasone.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Isoniazid.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Isoniazid.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Isoniazid.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Isoniazid.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Isoniazid.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Isoniazid.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Isoniazid.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isoniazid.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Isoniazid.Approved
BudesonideThe serum concentration of Isoniazid can be decreased when it is combined with Budesonide.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Isoniazid.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Isoniazid.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Isoniazid.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Isoniazid.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Isoniazid.Approved, Investigational
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Isoniazid.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Isoniazid.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CapsaicinThe metabolism of Capsaicin can be decreased when combined with Isoniazid.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Isoniazid.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Isoniazid.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Isoniazid.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Isoniazid.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Isoniazid.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Isoniazid.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Isoniazid.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Isoniazid.Approved, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Isoniazid.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Isoniazid.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Isoniazid.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Isoniazid.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Isoniazid.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Isoniazid.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Isoniazid.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Isoniazid.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Isoniazid.Approved
CiclesonideThe serum concentration of Isoniazid can be decreased when it is combined with Ciclesonide.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Isoniazid.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Isoniazid.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Isoniazid.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Isoniazid.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Isoniazid.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Isoniazid.Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Isoniazid.Approved, Illicit
ClobetasolThe serum concentration of Isoniazid can be decreased when it is combined with Clobetasol.Investigational
Clobetasol propionateThe serum concentration of Isoniazid can be decreased when it is combined with Clobetasol propionate.Approved
ClobetasoneThe serum concentration of Isoniazid can be decreased when it is combined with Clobetasone.Approved
ClocortoloneThe serum concentration of Isoniazid can be decreased when it is combined with Clocortolone.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Isoniazid.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Isoniazid.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Isoniazid.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Isoniazid resulting in a loss in efficacy.Approved, Nutraceutical
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Isoniazid.Approved, Illicit
ClotrimazoleThe metabolism of Isoniazid can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Isoniazid.Approved
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Isoniazid.Approved, Illicit
Cortexolone 17α-propionateThe serum concentration of Isoniazid can be decreased when it is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe serum concentration of Isoniazid can be decreased when it is combined with Corticosterone.Experimental
Cortisone acetateThe serum concentration of Isoniazid can be decreased when it is combined with Cortisone acetate.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Isoniazid.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Isoniazid.Approved, Investigational
CycloserineThe risk or severity of adverse effects can be increased when Isoniazid is combined with Cycloserine.Approved
Cyproterone acetateThe serum concentration of Isoniazid can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Isoniazid.Approved, Investigational
DalfampridineThe metabolism of Dalfampridine can be decreased when combined with Isoniazid.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Isoniazid.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Isoniazid.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Isoniazid.Approved, Investigational
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Isoniazid.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Isoniazid.Approved, Investigational
DeflazacortThe serum concentration of Isoniazid can be decreased when it is combined with Deflazacort.Approved
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Isoniazid.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Isoniazid.Approved
DesonideThe serum concentration of Isoniazid can be decreased when it is combined with Desonide.Approved, Investigational
DesoximetasoneThe serum concentration of Isoniazid can be decreased when it is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe serum concentration of Isoniazid can be decreased when it is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe serum concentration of Isoniazid can be decreased when it is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Isoniazid.Approved, Investigational
DexamethasoneThe serum concentration of Isoniazid can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Isoniazid can be decreased when it is combined with Dexamethasone isonicotinate.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Isoniazid.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Isoniazid.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Isoniazid.Approved
DexmedetomidineThe metabolism of Dexmedetomidine can be decreased when combined with Isoniazid.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Isoniazid.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Isoniazid.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Isoniazid.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Isoniazid.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Isoniazid.Approved, Vet Approved
DiflorasoneThe serum concentration of Isoniazid can be decreased when it is combined with Diflorasone.Approved
DifluocortoloneThe serum concentration of Isoniazid can be decreased when it is combined with Difluocortolone.Approved, Investigational
DifluprednateThe serum concentration of Isoniazid can be decreased when it is combined with Difluprednate.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Isoniazid.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Isoniazid.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Isoniazid.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Isoniazid.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Isoniazid.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Isoniazid.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Isoniazid.Approved
DisulfiramThe risk or severity of adverse effects can be increased when Disulfiram is combined with Isoniazid.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Isoniazid.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Isoniazid.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Isoniazid.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Isoniazid.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Isoniazid.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Isoniazid.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Isoniazid.Approved, Investigational
DronabinolThe metabolism of Dronabinol can be decreased when combined with Isoniazid.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Isoniazid.Approved
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Isoniazid.Approved
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Isoniazid.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Isoniazid.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Isoniazid.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Isoniazid.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Isoniazid.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Isoniazid.Investigational
EnfluraneThe metabolism of Enflurane can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Isoniazid.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Isoniazid.Approved, Investigational
EquileninThe serum concentration of Isoniazid can be decreased when it is combined with Equilenin.Experimental
EquilinThe serum concentration of Isoniazid can be decreased when it is combined with Equilin.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Isoniazid.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Isoniazid.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Isoniazid.Approved, Investigational
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Isoniazid.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Isoniazid.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Isoniazid.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Isoniazid can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Isoniazid can be decreased when it is combined with Estrone sulfate.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Isoniazid.Approved
Ethanolamine OleateThe metabolism of Ethanolamine Oleate can be decreased when combined with Isoniazid.Approved
EthionamideThe serum concentration of Isoniazid can be increased when it is combined with Ethionamide.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Isoniazid.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Isoniazid.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Isoniazid.Approved
EtoposideThe metabolism of Etoposide can be decreased when combined with Isoniazid.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Isoniazid.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Isoniazid.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Isoniazid.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Isoniazid.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Isoniazid.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Isoniazid.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Isoniazid.Approved, Withdrawn
fluasteroneThe serum concentration of Isoniazid can be decreased when it is combined with fluasterone.Investigational
FludrocortisoneThe serum concentration of Isoniazid can be decreased when it is combined with Fludrocortisone.Approved
FlumethasoneThe serum concentration of Isoniazid can be decreased when it is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Isoniazid.Approved
FlunisolideThe serum concentration of Isoniazid can be decreased when it is combined with Flunisolide.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Isoniazid.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Isoniazid can be decreased when it is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Isoniazid can be decreased when it is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe serum concentration of Isoniazid can be decreased when it is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe serum concentration of Isoniazid can be decreased when it is combined with Fluorometholone.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Isoniazid.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Isoniazid.Approved
FluprednideneThe serum concentration of Isoniazid can be decreased when it is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe serum concentration of Isoniazid can be decreased when it is combined with Fluprednisolone.Approved
FlurandrenolideThe serum concentration of Isoniazid can be decreased when it is combined with Flurandrenolide.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Isoniazid.Approved
Fluticasone furoateThe serum concentration of Isoniazid can be decreased when it is combined with Fluticasone furoate.Approved
Fluticasone propionateThe serum concentration of Isoniazid can be decreased when it is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Isoniazid.Approved
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Isoniazid.Approved, Investigational
Folic AcidThe metabolism of Folic Acid can be decreased when combined with Isoniazid.Approved, Nutraceutical, Vet Approved
FormestaneThe serum concentration of Isoniazid can be decreased when it is combined with Formestane.Approved, Investigational, Withdrawn
FormoterolThe metabolism of Formoterol can be decreased when combined with Isoniazid.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Isoniazid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Isoniazid.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Isoniazid.Approved, Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Isoniazid.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Isoniazid.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Isoniazid.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Isoniazid.Approved, Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Isoniazid.Approved, Investigational
HalcinonideThe serum concentration of Isoniazid can be decreased when it is combined with Halcinonide.Approved, Investigational, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Isoniazid.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Isoniazid.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Isoniazid.Approved, Vet Approved
HE3286The serum concentration of Isoniazid can be decreased when it is combined with HE3286.Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Isoniazid.Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Isoniazid.Approved, Illicit
HydrocortisoneThe serum concentration of Isoniazid can be decreased when it is combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Isoniazid.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Isoniazid.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Isoniazid.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Isoniazid.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Isoniazid.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Isoniazid.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Isoniazid.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Isoniazid.Approved
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Isoniazid.Approved, Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Isoniazid.Approved
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Isoniazid.Approved, Vet Approved
IstaroximeThe serum concentration of Isoniazid can be decreased when it is combined with Istaroxime.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Isoniazid.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Isoniazid.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Isoniazid.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Isoniazid.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Isoniazid.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Isoniazid.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Isoniazid.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Isoniazid.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Isoniazid.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Isoniazid.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Isoniazid.Approved, Vet Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Isoniazid.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Isoniazid.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Isoniazid.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Isoniazid.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Isoniazid.Approved
LoteprednolThe serum concentration of Isoniazid can be decreased when it is combined with Loteprednol.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Isoniazid.Approved, Investigational
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Isoniazid.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Isoniazid.Illicit, Investigational, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Isoniazid.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Isoniazid.Approved
ME-609The serum concentration of Isoniazid can be decreased when it is combined with ME-609.Investigational
MedrysoneThe serum concentration of Isoniazid can be decreased when it is combined with Medrysone.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Isoniazid.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Isoniazid can be decreased when it is combined with Melengestrol.Vet Approved
MenadioneThe metabolism of Menadione can be decreased when combined with Isoniazid.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Isoniazid.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Isoniazid.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Isoniazid.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Isoniazid.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Isoniazid.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Isoniazid.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Isoniazid.Approved, Illicit
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Isoniazid.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Isoniazid.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Isoniazid.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Isoniazid.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Isoniazid.Approved
MethylprednisoloneThe serum concentration of Isoniazid can be decreased when it is combined with Methylprednisolone.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Isoniazid.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Isoniazid.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Isoniazid.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Isoniazid.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Isoniazid.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Isoniazid.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Isoniazid.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Isoniazid.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Isoniazid.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Isoniazid.Approved
MitoxantroneThe metabolism of Mitoxantrone can be decreased when combined with Isoniazid.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Isoniazid.Approved
MometasoneThe serum concentration of Isoniazid can be decreased when it is combined with Mometasone.Approved, Vet Approved
MorphineThe metabolism of Morphine can be decreased when combined with Isoniazid.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Isoniazid.Approved, Investigational
NCX 1022The serum concentration of Isoniazid can be decreased when it is combined with NCX 1022.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Isoniazid.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Isoniazid.Approved, Withdrawn
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Isoniazid.Approved
NetupitantThe metabolism of Netupitant can be decreased when combined with Isoniazid.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Isoniazid.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Isoniazid.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Isoniazid.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Isoniazid.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Isoniazid.Approved
NilutamideThe metabolism of Nilutamide can be decreased when combined with Isoniazid.Approved
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Isoniazid.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Isoniazid.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Isoniazid.Approved, Investigational
Oleoyl-estroneThe serum concentration of Isoniazid can be decreased when it is combined with Oleoyl-estrone.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Isoniazid.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Isoniazid.Approved
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Isoniazid.Approved, Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Isoniazid.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Isoniazid.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Isoniazid.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Isoniazid.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Isoniazid.Approved
ParamethasoneThe serum concentration of Isoniazid can be decreased when it is combined with Paramethasone.Approved
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Isoniazid.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Isoniazid.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Isoniazid.Approved
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Isoniazid.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Isoniazid.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Isoniazid.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Isoniazid.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Isoniazid.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Isoniazid.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Isoniazid.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Isoniazid.Approved, Investigational, Withdrawn
PhenobarbitalThe metabolism of Phenobarbital can be decreased when combined with Isoniazid.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Isoniazid.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Isoniazid.Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Isoniazid.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Isoniazid.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Isoniazid.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Isoniazid.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Isoniazid.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Isoniazid.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Isoniazid.Approved
PrasteroneThe serum concentration of Isoniazid can be decreased when it is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of Isoniazid can be decreased when it is combined with Prasterone sulfate.Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Isoniazid.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Isoniazid.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Isoniazid.Approved, Vet Approved
PrednicarbateThe serum concentration of Isoniazid can be decreased when it is combined with Prednicarbate.Approved
PrednisoloneThe serum concentration of Isoniazid can be decreased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Isoniazid can be decreased when it is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe serum concentration of Isoniazid can be decreased when it is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Primidone can be decreased when combined with Isoniazid.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Isoniazid.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Isoniazid.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Isoniazid.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Isoniazid.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Isoniazid.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Isoniazid.Approved
PropacetamolIsoniazid may increase the hepatotoxic activities of Propacetamol.Approved, Investigational
PropafenoneThe serum concentration of Isoniazid can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Isoniazid.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Isoniazid.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Isoniazid.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Isoniazid.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Isoniazid.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Isoniazid.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Isoniazid.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Isoniazid.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Isoniazid.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Isoniazid.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Isoniazid.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Isoniazid.Investigational
RifabutinRifabutin may increase the hepatotoxic activities of Isoniazid.Approved
RifampicinRifampicin may increase the hepatotoxic activities of Isoniazid.Approved
RifapentineRifapentine may increase the hepatotoxic activities of Isoniazid.Approved
RifaximinRifaximin may increase the hepatotoxic activities of Isoniazid.Approved, Investigational
RimexoloneThe serum concentration of Isoniazid can be decreased when it is combined with Rimexolone.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Isoniazid.Approved, Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Isoniazid.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Isoniazid.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Isoniazid.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Isoniazid.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Isoniazid.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Isoniazid.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Isoniazid.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Isoniazid.Approved, Investigational
SelegilineThe metabolism of Selegiline can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Isoniazid.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Isoniazid.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Isoniazid.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Isoniazid.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Isoniazid.Approved, Investigational
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Isoniazid.Approved
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Isoniazid.Experimental
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Isoniazid.Approved, Vet Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Isoniazid resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Isoniazid.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Isoniazid.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Isoniazid.Investigational, Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Isoniazid.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Isoniazid.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Isoniazid.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Isoniazid.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Isoniazid.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Isoniazid.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Isoniazid.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Isoniazid.Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Isoniazid.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Isoniazid.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Isoniazid.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Isoniazid.Approved, Withdrawn
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Isoniazid.Approved
TimololThe metabolism of Timolol can be decreased when combined with Isoniazid.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Isoniazid.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Isoniazid.Approved, Investigational
TirapazamineThe metabolism of Tirapazamine can be decreased when combined with Isoniazid.Investigational
TixocortolThe serum concentration of Isoniazid can be decreased when it is combined with Tixocortol.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Isoniazid.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Isoniazid.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Isoniazid.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Isoniazid.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Isoniazid.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Isoniazid.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Isoniazid.Approved, Investigational
TriamcinoloneThe serum concentration of Isoniazid can be decreased when it is combined with Triamcinolone.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Isoniazid.Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Isoniazid.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Isoniazid.Investigational, Withdrawn
TromethamineTromethamine can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Isoniazid.Approved, Investigational, Nutraceutical
UlobetasolThe serum concentration of Isoniazid can be decreased when it is combined with Ulobetasol.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Isoniazid.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Isoniazid.Approved, Investigational
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Isoniazid.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Isoniazid.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Isoniazid.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Isoniazid.Approved, Investigational
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Isoniazid.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Isoniazid.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Isoniazid.Approved, Investigational
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Isoniazid.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Isoniazid.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Isoniazid.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Isoniazid.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Isoniazid.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Isoniazid.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Isoniazid.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Isoniazid.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Isoniazid.Approved, Investigational
Food Interactions
  • Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

References

Synthesis Reference

Costin Rentzea, Albrecht Harreus, Eberhard Ammermann, Gisela Lorenz, "Oxalyl hydrazide-hydroxamic acid derivatives, their preparation and their use as fungicides." U.S. Patent US5399589, issued November, 1969.

US5399589
General References
Not Available
External Links
Human Metabolome Database
HMDB15086
KEGG Drug
D00346
KEGG Compound
C07054
PubChem Compound
3767
PubChem Substance
46506039
ChemSpider
3635
BindingDB
50336507
ChEBI
6030
ChEMBL
CHEMBL64
Therapeutic Targets Database
DAP000011
PharmGKB
PA450112
HET
NIZ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Isoniazid
ATC Codes
J04AM04 — Thioacetazone and isoniazidJ04AM02 — Rifampicin and isoniazidJ04AM06 — Rifampicin, pyrazinamide, ethambutol and isoniazidJ04AM05 — Rifampicin, pyrazinamide and isoniazidJ04AM01 — Streptomycin and isoniazidJ04AM03 — Ethambutol and isoniazidJ04AC51 — Isoniazid, combinationsJ04AC01 — Isoniazid
AHFS Codes
  • 08:16.04 — Antituberculosis Agents
PDB Entries
3wxo / 4pae / 5ksg / 5ksn / 5kt8 / 5sxq / 5sxs / 5sxt / 5syi / 5syj
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedOtherTuberculosis2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis2
1CompletedTreatmentTuberculosis2
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1RecruitingTreatmentTuberculosis1
1, 2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentTB Multi-drug Resistant1
1, 2RecruitingTreatmentTuberculosis1
1, 2RecruitingTreatmentTuberculous Meningitis1
2Active Not RecruitingTreatmentTuberculosis1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2CompletedTreatmentTuberculosis3
2CompletedTreatmentTuberculosis, Pulmonary1
2Not Yet RecruitingTreatmentDrug-resistant Tuberculosis / Drug-Resistant Tuberculosis, Extremely / Tuberculosis / Tuberculosis, MDR / Tuberculosis, Multidrug Resistant / Tuberculosis, Pulmonary1
2RecruitingPreventionTuberculosis1
2RecruitingTreatmentTuberculosis2
2SuspendedTreatmentTuberculosis1
2SuspendedTreatmentTuberculosis, Pulmonary1
2Unknown StatusTreatmentTuberculosis1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2, 3CompletedTreatmentTuberculosis, Multidrug Resistant1
2, 3Not Yet RecruitingPreventionTuberculosis1
2, 3RecruitingTreatmentExtensively-drug Resistant Tuberculosis / Tuberculosis / Tuberculosis, Multidrug Resistant1
2, 3RecruitingTreatmentTuberculosis, Pulmonary1
2, 3TerminatedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Interstitial Plasma Cell / Tuberculosis1
3Active Not RecruitingPreventionLatent Tuberculosis Infection (LTI)1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis, Pulmonary1
3Active Not RecruitingTreatmentTuberculosis, Pulmonary, Drug Sensitive / Tuberculosis, Pulmonary, Multi Drug-resistant1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis2
3CompletedPreventionHuman Immunodeficiency Virus (HIV) / Tuberculosis1
3CompletedPreventionLatent Tuberculosis Infection (LTI)1
3CompletedPreventionTuberculosis1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections / Tuberculosis1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
3CompletedTreatmentLatent Tuberculosis Infection (LTI)2
3CompletedTreatmentTuberculosis3
3CompletedTreatmentTuberculosis, Pulmonary2
3RecruitingPreventionHuman Immunodeficiency Virus (HIV) / Tuberculosis1
3RecruitingPreventionSilicosis / Tuberculosis1
3RecruitingTreatmentMDR-TB1
3RecruitingTreatmentTuberculosis1
3TerminatedTreatmentInfection in Solid Organ Transplant Recipients / Latent Tuberculosis Infection (LTI)1
3TerminatedTreatmentMultiple System Atrophy (MSA)1
3TerminatedTreatmentTuberculosis, Pulmonary1
3Unknown StatusPreventionTuberculosis1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
4Active Not RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
4Active Not RecruitingPreventionInfection, Human Immunodeficiency Virus I1
4Active Not RecruitingTreatmentDiabetes Mellitus (DM) / Tuberculin (Skin Test) Positive1
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4CompletedDiagnosticTuberculosis1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
4CompletedTreatmentTuberculosis, Pulmonary1
4Not Yet RecruitingHealth Services ResearchAddictions / Hepatitis / HIV-infection/Aids / Opioid Dependence / Tuberculosis1
4Not Yet RecruitingTreatmentCompliance, Patient1
4RecruitingOtherAlcohol Abuse / HIV-infection/Aids / Tuberculosis1
4RecruitingTreatmentAIDS With Tuberculosis1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4RecruitingTreatmentTuberculosis, Pulmonary1
4RecruitingTreatmentTuberculosis, Spinal1
4Unknown StatusPreventionHuman Immunodeficiency Virus (HIV) / Latent Tuberculosis Infection (LTI) / Tuberculosis (TB)1
4Unknown StatusTreatmentHepatitis / Tuberculosis, Pulmonary1
4Unknown StatusTreatmentHepatotoxicity / Tuberculosis1
4Unknown StatusTreatmentReinfection Pulmonary Tuberculosis1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Latent Tuberculosis Infection (LTI) / Tuberculosis1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
Not AvailableCompletedSupportive CareBody Weight Changes / Motor Activities / Tuberculosis, Pulmonary1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis4
Not AvailableCompletedTreatmentKidney Transplant Recipients1
Not AvailableCompletedTreatmentTuberculosis2
Not AvailableRecruitingTreatmentDrug-resistant Tuberculosis / Tuberculosis / Tuberculosis, Multidrug Resistant1
Not AvailableTerminatedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Tuberculosis1
Not AvailableTerminatedTreatmentErythropoietic Protoporphyria (EPP) / X Linked Erythropoietic Protoporphyria1
Not AvailableUnknown StatusNot AvailableTuberculosis, Pulmonary1
Not AvailableUnknown StatusPreventionTuberculosis1
Not AvailableUnknown StatusSupportive CareHepatotoxicity1
Not AvailableUnknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1

Pharmacoeconomics

Manufacturers
  • Sandoz canada inc
  • Sandoz inc
  • Hoffmann la roche inc
  • Carolina medical products co
  • Mikart inc
  • Lannett co inc
  • Dow pharmaceutical corp sub dow chemical co
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Novartis pharmaceuticals corp
  • Barr laboratories inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Halsey drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Eli lilly and co
  • Mk laboratories inc
  • Mutual pharmaceutical co inc
  • Nexgen pharma inc
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Pharmavite pharmaceuticals
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Bristol myers squibb co
  • Everylife
Packagers
Dosage forms
FormRouteStrength
CapsuleOral
Injection, solutionIntramuscular100 mg/mL
SolutionOral50 mg/5mL
SyrupOral50 mg/5mL
TabletOral100 mg/1
TabletOral300 mg/1
SyrupOral50 mg
TabletOral50 mg
PowderOral500 g
SyrupOral10 mg
SolutionOral50 mg
TabletOral100 mg
TabletOral300 mg
TabletOral
Tablet, sugar coatedOral
Prices
Unit descriptionCostUnit
Isoniazid 100 mg/ml vial27.37USD ml
Rifamate 150-300 mg capsule4.36USD capsule
Rifamate capsule4.19USD capsule
Isoniazid 100 mg tablet0.28USD tablet
Isoniazid 300 mg tablet0.18USD tablet
Isoniazid 50 mg/5ml Syrup0.16USD ml
Isoniazid powder0.11USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)171.4 °CPhysProp
water solubility1.4E+005 mg/L (at 25 °C)MERCK INDEX (2001)
logP-0.70HANSCH,C ET AL. (1995)
logS0.01ADME Research, USCD
pKa1.82 (at 20 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility34.9 mg/mLALOGPS
logP-0.71ALOGPS
logP-0.69ChemAxon
logS-0.59ALOGPS
pKa (Strongest Acidic)13.61ChemAxon
pKa (Strongest Basic)3.35ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area68.01 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity37.46 m3·mol-1ChemAxon
Polarizability13.21 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9892
Blood Brain Barrier+0.9895
Caco-2 permeable+0.6959
P-glycoprotein substrateNon-substrate0.8315
P-glycoprotein inhibitor INon-inhibitor0.9778
P-glycoprotein inhibitor IINon-inhibitor0.996
Renal organic cation transporterNon-inhibitor0.9054
CYP450 2C9 substrateNon-substrate0.9088
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateInhibitor0.6482
CYP450 2C9 inhibitorNon-inhibitor0.9273
CYP450 2D6 inhibitorNon-inhibitor0.9443
CYP450 2C19 inhibitorNon-inhibitor0.9513
CYP450 3A4 inhibitorNon-inhibitor0.5111
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9342
Ames testAMES toxic0.8557
CarcinogenicityNon-carcinogens0.7514
BiodegradationNot ready biodegradable0.981
Rat acute toxicity2.0713 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9872
hERG inhibition (predictor II)Non-inhibitor0.9586
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.21 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0kdr-9600000000-f04526999a9b68d31861
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-0900000000-3cf8f43d0df46334dcd9
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-052r-7900000000-3d43394feacded48669d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004i-9000000000-263a0bcadf2e21536983
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-002f-9000000000-17100430370d37f834ce
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9000000000-9466b9291244c1a61f01
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-0900000000-afcf227eec118bec08a4
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-1900000000-d63af1f463124dbf7b65
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00fr-9600000000-1d50dedb0eea7ff8dccb
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-004i-9100000000-371fd6d67c48f373e2e5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-004i-9000000000-dee0012ebd004444b3d8
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridinecarboxylic acids and derivatives
Direct Parent
Pyridinecarboxylic acids and derivatives
Alternative Parents
Heteroaromatic compounds / Carboxylic acid hydrazides / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Pyridine carboxylic acid or derivatives / Heteroaromatic compound / Carboxylic acid hydrazide / Azacycle / Carboxylic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
carbohydrazide (CHEBI:6030) / a small molecule (ISONIAZIDE)

Targets

Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Yes
Actions
Other/unknown
General Function
Bifunctional enzyme with both catalase and broad-spectrum peroxidase activity, oxidizing various electron donors including NADP(H) (PubMed:9006925, PubMed:18178143). Protects M.tuberculosis against toxic reactive oxygen species (ROS) including hydrogen peroxide as well as organic peroxides and thus contributes to its survival within host macrophages by countering the phagocyte oxidative burst (PubMed:8658136, PubMed:15165233). Also displays efficient peroxynitritase activity, which may help the bacterium to persist in macrophages (PubMed:10080924).
Specific Function
Catalase activity
Gene Name
katG
Uniprot ID
P9WIE5
Uniprot Name
Catalase-peroxidase
Molecular Weight
80604.275 Da
References
  1. Pym AS, Domenech P, Honore N, Song J, Deretic V, Cole ST: Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. Mol Microbiol. 2001 May;40(4):879-89. [PubMed:11401695]
  2. Heym B, Alzari PM, Honore N, Cole ST: Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol. 1995 Jan;15(2):235-45. [PubMed:7746145]
  3. Wilson TM, de Lisle GW, Collins DM: Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol. 1995 Mar;15(6):1009-15. [PubMed:7623658]
  4. Vilcheze C, Jacobs WR Jr: The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol. 2007;61:35-50. [PubMed:18035606]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Yes
Actions
Adduct
General Function
Enoyl-ACP reductase of the type II fatty acid syntase (FAS-II) system, which is involved in the biosynthesis of mycolic acids, a major component of mycobacterial cell walls (PubMed:25227413). Catalyzes the NADH-dependent reduction of the double bond of 2-trans-enoyl-[acyl-carrier protein], an essential step in the fatty acid elongation cycle of the FAS-II pathway (PubMed:7599116). Shows preference for long-chain fatty acyl thioester substrates (>C16), and can also use 2-trans-enoyl-CoAs as alternative substrates (PubMed:7599116). The mycobacterial FAS-II system utilizes the products of the FAS-I system as primers to extend fatty acyl chain lengths up to C56, forming the meromycolate chain that serves as the precursor for final mycolic acids (PubMed:25227413).
Specific Function
Enoyl-[acyl-carrier-protein] reductase (nadh) activity
Gene Name
inhA
Uniprot ID
P9WGR1
Uniprot Name
Enoyl-[acyl-carrier-protein] reductase [NADH]
Molecular Weight
28527.55 Da
References
  1. Schroeder EK, Basso LA, Santos DS, de Souza ON: Molecular dynamics simulation studies of the wild-type, I21V, and I16T mutants of isoniazid-resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: toward the understanding of NADH-InhA different affinities. Biophys J. 2005 Aug;89(2):876-84. Epub 2005 May 20. [PubMed:15908576]
  2. Wilson TM, de Lisle GW, Collins DM: Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol. 1995 Mar;15(6):1009-15. [PubMed:7623658]
  3. Broussy S, Coppel Y, Nguyen M, Bernadou J, Meunier B: 1H and 13C NMR characterization of hemiamidal isoniazid-NAD(H) adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis. Chemistry. 2003 May 9;9(9):2034-8. [PubMed:12740851]
  4. Vilcheze C, Jacobs WR Jr: The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol. 2007;61:35-50. [PubMed:18035606]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Fontana E, Dansette PM, Poli SM: Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab. 2005 Oct;6(5):413-54. [PubMed:16248836]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Fontana E, Dansette PM, Poli SM: Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab. 2005 Oct;6(5):413-54. [PubMed:16248836]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Fontana E, Dansette PM, Poli SM: Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab. 2005 Oct;6(5):413-54. [PubMed:16248836]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Fontana E, Dansette PM, Poli SM: Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab. 2005 Oct;6(5):413-54. [PubMed:16248836]
Details
7. Dihydrofolate reductase
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
General Function
Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.
Specific Function
Dihydrofolate reductase activity
Gene Name
folA
Uniprot ID
P9WNX1
Uniprot Name
Dihydrofolate reductase
Molecular Weight
17872.18 Da
References
  1. Wang F, Jain P, Gulten G, Liu Z, Feng Y, Ganesula K, Motiwala AS, Ioerger TR, Alland D, Vilcheze C, Jacobs WR Jr, Sacchettini JC: Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob Agents Chemother. 2010 Sep;54(9):3776-82. doi: 10.1128/AAC.00453-10. Epub 2010 Jun 21. [PubMed:20566771]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
2. Cytochrome P450 1A2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
5. Cytochrome P450 2C19
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
6. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Arylamine n-acetyltransferase activity
Specific Function
Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivat...
Gene Name
NAT2
Uniprot ID
P11245
Uniprot Name
Arylamine N-acetyltransferase 2
Molecular Weight
33542.235 Da
References
  1. Upton AM, Mushtaq A, Victor TC, Sampson SL, Sandy J, Smith DM, van Helden PV, Sim E: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol Microbiol. 2001 Oct;42(2):309-17. [PubMed:11703656]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Catalyzes the transfer of the acetyl group from acetyl coenzyme A to the free amino group of arylamines and hydrazines (PubMed:18795795). Is able to utilize not only acetyl-CoA, but also n-propionyl-CoA and acetoacetyl-CoA as acyl donors, although at a lower rate (PubMed:19014350). As acetyl-CoA and propionyl-CoA are products of cholesterol catabolism and the nat gene is likely present in the same operon than genes involved in cholesterol degradation, this enzyme could have a role in the utilization and regulation of these CoA species (PubMed:19014350).
Specific Function
Arylamine n-acetyltransferase activity
Gene Name
nat
Uniprot ID
P9WJI5
Uniprot Name
Arylamine N-acetyltransferase
Molecular Weight
31028.88 Da
References
  1. Upton AM, Mushtaq A, Victor TC, Sampson SL, Sandy J, Smith DM, van Helden PV, Sim E: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol Microbiol. 2001 Oct;42(2):309-17. [PubMed:11703656]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Meng X, Maggs JL, Usui T, Whitaker P, French NS, Naisbitt DJ, Park BK: Auto-oxidation of Isoniazid Leads to Isonicotinic-Lysine Adducts on Human Serum Albumin. Chem Res Toxicol. 2015 Jan 20;28(1):51-8. doi: 10.1021/tx500285k. Epub 2014 Dec 9. [PubMed:25489718]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18